New drug could provide faster relief for postnatal depression
Postnatal depression affects an estimated 10-20% of women worldwide, exposing them to a higher risk of morbidity and mortality.
We also know that if a mother with postnatal depression is untreated, the infant is more likely to experience difficulty with emotional regulation in their early years, which can affect social behaviour in adolescence.
It is perhaps surprising that, given the social and economic burdens, there are no specific pharmacological therapies for postnatal depression.
Those women who do receive treatment, such as SSRIs, are less